Eternity Healthcare Inc. announced that it has completed patient selection for the clinical trial comparing the Comfort-in(TM) Needle-free Injection System versus the standard needle process, for patients undergoing fertility treatments using the drug Gonadotropins. In the clinical trial there will be 10 groups of six patients each. The clinical trial will be an open label randomized trial carried out under the supervision of a lead investigator at the Pacific Center for Reproductive Medicine.

The clinical trial will not only monitor the Comfort-in(TM) Needle-free Injection System's ability to deliver the same quantity of drugs to the patients as the regular needle, but will observe the patients pain trauma, along with a physiological observation. The clinical trial will involve women patients that require stimulation by the fertility drug Gonadotropins for their first superovulation cycle. Gonadotropin is a fertility drug that contains follicle stimulation hormone (FSH), luteinizing hormone (LH) or a combination of the two drugs.

Gonadotropin is a natural hormone already in a woman's body that plays a role in the production of eggs and eventual ovulation. This natural hormone Gonadotropins may be used on its own or as a part of an IUI treatment or IVF treatment cycle. Synthetic gonadotropins and analogs are marketed by major pharmaceutical companies such as Astra Zeneca, Sanofi Aventis, Bayer AG, Pfizer and Abbott Laboratories, etc.